Literature DB >> 32363506

Self-reported needs of patients with Parkinson's disease during COVID-19 emergency in Italy.

Tommaso Schirinzi1, Rocco Cerroni2, Giulia Di Lazzaro2, Claudio Liguori2, Simona Scalise2, Roberta Bovenzi2, Matteo Conti2, Elena Garasto2, Nicola Biagio Mercuri2,3, Mariangela Pierantozzi2, Antonio Pisani2,3, Alessandro Stefani2.   

Abstract

Because of COVID-19 outbreak, regular clinical services for Parkinson's disease (PD) patients have been suddenly suspended, causing worries, confusion and unexpected needs in such frail population. Here, we reviewed the messages spontaneously sent by patients to an Italian PD clinic during the first two weeks of COVID-19 lockdown (9-21 March 2020), in order to highlight their main needs and then outline appropriate strategies of care for this critical period. One hundred sixty-two messages were analysed. Forty-six percent queried about clinical services; 28% communicated an acute clinical worsening for which a therapeutic change was done in 52% of cases; 17% (those patients with younger age and milder disease) asked about the relationship between PD and COVID-19; 8% informed about an intercurrent event. Our analysis suggests that PD patients' needs during COVID-19 emergency include appropriate and complete information, a timely update on changes in clinical services, and the continuity of care, even in a remote mode. By addressing these issues, acute clinical worsening, complications and subsequent therapeutic changes could be prevented. In this perspective, telecommunication systems and virtual medicine should be implemented.

Entities:  

Keywords:  COVID-19; Coronavirus; Neurological diseases; Parkinson’s disease; Telemedicine

Mesh:

Year:  2020        PMID: 32363506      PMCID: PMC7196180          DOI: 10.1007/s10072-020-04442-1

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


Introduction

Italy was hardly scourged by Coronavirus disease 2019 (COVID-19) pandemia [1] and, on 9 March 2020, extraordinary measures (lockdown) have been ordered. Hospitals’ routine activities were stopped [1] and a huge number of neurologists were employed to treat COVID-19 patients. Therefore, follow-up visits and scheduled activities for patients with Parkinson’s disease (PD) were suddenly suspended. Media provided continuous information on facts related to COVID-19 outbreak; however, sometimes, it turns out to be incomplete or inappropriate [2]. The lack of adequate information, together with the emergency’s spread and the regular clinical services’ suspension, caused worries and confusion in PD patients, which massively contacted their doctors for several questions. In this study, we collected the major queries raised by patients from a PD clinic of a single Italian centre over the first two weeks of COVID-19 lockdown. We aimed to focus their main needs and identify opportune strategies to adequately assist PD patients during this emergency.

Methods

E-mails, phone texts and phone vocal messages spontaneously sent form PD patients or caregivers to the PD Clinic of Tor Vergata University Hospital (Rome, Italy) from 9 to 21 March 2020 were collected and analysed. Queries and communications (Q) were classified in 4 groups depending on the content: (Q1) relationship between COVID-19 and PD; (Q2) acute changes in neurological symptoms; (Q3) occurrence of intercurrent medical/surgical conditions; (Q4) clinical services. For each patient, age, sex, disease duration, Hoehn and Yahr (HY) stage and address were collected retrospectively from the electronic chart. Possible therapeutic modifications due to Q2 were recorded. The study followed local ethical standards and the principles of Helsinki declarations.

Statistical analysis

Distribution of continuous variables was assessed and non-normally distributed ones were Log10 transformed to allow statistical analysis. Descriptive statistic was calculated for categorical variables. Group differences were analysed by parametric or non-parametric tests, as appropriate (Software: IBM-SPSS).

Results

One hundred sixty-two communications were received, 89.2% from Rome area, 8.6% from South-Italy, and 2.2% from other northern-centre regions. Figure 1 a represents prevalence of queries. Q4 (about clinical services) was the most frequent (46%). Table 1 summarizes clinical-demographic parameters of patients. Age significantly differed (F(3,126) = 3.35; p = 0.02), being lower for Q1 (55.3 years) compared with Q4 (65.3) (Bonferroni post hoc, p = 0.01). As well, HY significantly differed (F(3,117) = 4.9; p = 0.003), being higher in Q3 (3.8) compared with Q1 (2.1) (p = 0.002).
Fig. 1

a Queries prevalence of PD patients. (Q1) Relationships between COVID-19 and PD; (Q2) changes in neurological symptoms occurred in that period; (Q3) occurrence of intercurrent medical/surgical conditions in that period; (Q4) clinical services. b and c Frequency of various items pertinent to Q2 and Q4. b Frequency of symptoms worsened during the lockdown. c Frequency of issues regarding clinical services interrupted by the lockdown. d. disturbances, other abbreviations spelled out in the text

Table 1

Demographic and clinical data of the study population

GroupNSex, F%/M%Age (y), mean (SD)Duration (y), mean (SD)HY, mean (SD)
All16246%/54%64.9 (13.1)8.9 (5.6)2.5 (0.9)
Q12853%/47%55.3 (12.3)6.9 (4.4)2.1 (0.9)
Q24654%/46%62.7 (16.4)8.9 (5.6)2.5 (0.9)
Q31346%/54%62.2 (14.4)13.7 (7.5)3.8 (0.9)
Q47540%/60%65.3 (11.9)9.1 (5.5)2.5 (0.9)

N, number; y, years; F/M, female/male. Other abbreviations spelled out in the text

a Queries prevalence of PD patients. (Q1) Relationships between COVID-19 and PD; (Q2) changes in neurological symptoms occurred in that period; (Q3) occurrence of intercurrent medical/surgical conditions in that period; (Q4) clinical services. b and c Frequency of various items pertinent to Q2 and Q4. b Frequency of symptoms worsened during the lockdown. c Frequency of issues regarding clinical services interrupted by the lockdown. d. disturbances, other abbreviations spelled out in the text Demographic and clinical data of the study population N, number; y, years; F/M, female/male. Other abbreviations spelled out in the text Forty-six patients referred acute clinical changes during the lockdown (Q2). Among these, 50% experienced an increase in motor disturbances (tremor, rigidity, gait difficulties); 25% had augmented anxiety and 18% developed/worsened neuropsychiatric symptoms (NPS, e.g. hallucinations, agitation, psychosis); 16% complained about other non-motor symptoms (NMS, e.g. fatigue, pain) (Fig. 1b). In 52.3% of Q2 patients, doctors provided therapeutic changes (in remote, according to standard clinical practice): in 33.3% of cases, the dopaminergic therapy was modified; in 41.7%, an anxiolytic drug (benzodiazepine) was introduced; in 25%, a neuroleptic was introduced/up-titrated. Q3 patients (those with higher HY stage) communicated an intercurrent medical/surgical event, which required in 46.2% of cases a hospital admission (1 decease). COVID-19 infection was suspected in 23.1% of them but confirmed in none. Q4 represented the most numerous group. Patients asked about confirmation of scheduled activities (e.g. visits, trials) in 47% of cases, required prescriptions for drugs or certifications in 57% and complained about the suspension of rehabilitation programmes (physiotherapy, PT) in 13% (Fig. 1c).

Discussion

We reviewed all queries and communications spontaneously provided by PD patients to an Italian PD clinic team during the first two weeks of the COVID-19 lockdown, in order to highlight their main needs and develop opportune strategies of assistance during this critical period. In 46% of cases, patients contacted for issues regarding clinical services, namely to be updated about scheduled activities (visits, trials), to ask for prescriptions or to complain about the suspension of PT. Twenty-eight percent of patients communicated an acute clinical worsening, in either motor disturbances or neuropsychiatric and other non-motor symptoms. Although none of these patients was affected by COVID-19, they experienced the worsening of their condition at the same time of the lockdown and the infection outbreak, consistently with the well-known detrimental effect of stress on PD symptomatology [3]. Fifty-two percent of these patients required therapeutic changes, often consisting of a higher use of benzodiazepines and neuroleptics, besides the adjustment of dopaminergic drugs. Seventeen percent of patients, specifically those younger, with a milder disease, contacted us to ask for clarification on the relationships between COVID-19 and PD, in particular on the risk of contracting the infection because of PD and its medications. Finally, 8% of patients, those more severely affected, communicated the appearance of an intercurrent medical/surgical event. COVID-19 disease was suspected but not confirmed in 3 of these patients. This study has several limitations. First, this is not a systematic structured survey on a PD population but a collection of self-reported communications, spontaneously provided by patients through e-mails, phone texts and vocal messages. Actually, needs from older, cognitively impaired and uneducated, or more severely affected patients could have been underestimated. Then, data came from the area of Rome, which was less affected by COVID-19 than other regions, limiting the generalization to the whole Italian population. Finally, we focussed on the beginning of the lockdown and the early phases of the COVID-19 emergency. Nevertheless, our analysis suggests that the main PD patients’ needs in this emergency were two. First, the correct and timely information. Indeed, an accurate communication with patients on the relations between PD and COVID-19 and an opportune update on the clinical services’ schedule might temper their stress and limit possible symptoms worsening, responsible, in turn, for unexpected therapeutic interventions. Second, the continuity of care, even in a “smart” mode. PD patients indeed require continuous treatments and regular checks. Accordingly, the boost of telemedicine and “virtual” visits or PT could be strikingly helpful, as well as the digitalization of different services. Web-based technologies and virtual telecommunication, although hindered by several limitations (the possible technical issues for older and advanced patients or privacy/bureaucracy concerns) [4, 5], thus represent the way to ensure the due care to PD patients during COVID-19 emergency.
  4 in total

Review 1.  Stress, depression and Parkinson's disease.

Authors:  Ann M Hemmerle; James P Herman; Kim B Seroogy
Journal:  Exp Neurol       Date:  2011-10-06       Impact factor: 5.330

2.  The Use of Digital Technology and Media in German Parkinson's Disease Patients.

Authors:  Franz Marxreiter; Ulrike Buttler; Heiko Gassner; Florin Gandor; Till Gladow; Bjoern Eskofier; Jürgen Winkler; Georg Ebersbach; Jochen Klucken
Journal:  J Parkinsons Dis       Date:  2020       Impact factor: 5.568

3.  National Randomized Controlled Trial of Virtual House Calls for People with Parkinson's Disease: Interest and Barriers.

Authors:  E Ray Dorsey; Meredith A Achey; Christopher A Beck; Denise B Beran; Kevin M Biglan; Cynthia M Boyd; Peter N Schmidt; Richard Simone; Allison W Willis; Nicholas B Galifianakis; Maya Katz; Caroline M Tanner; Kristen Dodenhoff; Nathan Ziman; Jason Aldred; Julie Carter; Joohi Jimenez-Shahed; Christine Hunter; Meredith Spindler; Zoltan Mari; John C Morgan; Dedi McLane; Patrick Hickey; Lisa Gauger; Irene Hegeman Richard; Michael T Bull; Nicte I Mejia; Grace Bwala; Martha Nance; Ludy Shih; Lauren Anderson; Carlos Singer; Cindy Zadikoff; Natalia Okon; Andrew Feigin; Jean Ayan; Christina Vaughan; Rajesh Pahwa; Jessica Cooper; Sydney Webb; Rohit Dhall; Anhar Hassan; Delana Weis; Steven DeMello; Sara S Riggare; Paul Wicks; Joseph Smith; H Tait Keenan; Ryan Korn; Heidi Schwarz; Saloni Sharma; E Anna Stevenson; William Zhu
Journal:  Telemed J E Health       Date:  2016-02-17       Impact factor: 3.536

4.  Toning down the 2019-nCoV media hype-and restoring hope.

Authors:  Giuseppe Ippolito; David S Hui; Francine Ntoumi; Markus Maeurer; Alimuddin Zumla
Journal:  Lancet Respir Med       Date:  2020-02-12       Impact factor: 30.700

  4 in total
  24 in total

1.  Spotlight on non-motor symptoms and Covid-19.

Authors:  Silvia Rota; Iro Boura; Yi-Min Wan; Claudia Lazcano-Ocampo; Mayela Rodriguez-Violante; Angelo Antonini; Kallol Ray Chaudhuri
Journal:  Int Rev Neurobiol       Date:  2022-07-09       Impact factor: 4.280

2.  A Self-Reported Clinical Tool Predicts Falls in People with Parkinson's Disease.

Authors:  Lorena Rosa S Almeida; Maria Elisa Pimentel Piemonte; Helen M Cavalcanti; Colleen G Canning; Serene S Paul
Journal:  Mov Disord Clin Pract       Date:  2021-03-11

3.  Correlates of Psychological Distress in Patients with Parkinson's Disease During the COVID-19 Outbreak.

Authors:  Rosa De Micco; Mattia Siciliano; Valeria Sant'Elia; Alfonso Giordano; Antonio Russo; Gioacchino Tedeschi; Alessandro Tessitore
Journal:  Mov Disord Clin Pract       Date:  2020-11-13

4.  Experiencing COVID19 pandemic and neurology: learning by the recent reports and by old literary or scientific descriptions.

Authors:  Antonio Federico
Journal:  Neurol Sci       Date:  2020-06       Impact factor: 3.307

Review 5.  COVID-19 and possible links with Parkinson's disease and parkinsonism: from bench to bedside.

Authors:  David Sulzer; Angelo Antonini; Valentina Leta; Anna Nordvig; Richard J Smeyne; James E Goldman; Osama Al-Dalahmah; Luigi Zecca; Alessandro Sette; Luigi Bubacco; Olimpia Meucci; Elena Moro; Ashley S Harms; Yaqian Xu; Stanley Fahn; K Ray Chaudhuri
Journal:  NPJ Parkinsons Dis       Date:  2020-08-20

Review 6.  Severe acute respiratory syndrome coronavirus 2 may be an underappreciated pathogen of the central nervous system.

Authors:  S B Alam; S Willows; M Kulka; J K Sandhu
Journal:  Eur J Neurol       Date:  2020-08-14       Impact factor: 6.288

7.  A collaborative approach to exercise provision for people with Parkinson's - a feasibility and acceptability study of the PDConnect programme [version 2; peer review: 2 approved].

Authors:  Julie Jones; Lyndsay Alexander; Elizabeth Hancock; Kay Cooper
Journal:  AMRC Open Res       Date:  2021-04-01

8.  The Impact of the COVID-19 Pandemic on Psychological Distress, Physical Activity, and Symptom Severity in Parkinson's Disease.

Authors:  Anouk van der Heide; Marjan J Meinders; Bastiaan R Bloem; Rick C Helmich
Journal:  J Parkinsons Dis       Date:  2020       Impact factor: 5.568

9.  The Effect of the COVID-19 Pandemic on People with Parkinson's Disease.

Authors:  Ethan G Brown; Lana M Chahine; Samuel M Goldman; Monica Korell; Emerald Mann; Daniel R Kinel; Vanessa Arnedo; Kenneth L Marek; Caroline M Tanner
Journal:  J Parkinsons Dis       Date:  2020       Impact factor: 5.568

10.  Impact of Coronavirus Disease 2019 Pandemic on Parkinson's Disease: A Cross-Sectional Survey of 568 Spanish Patients.

Authors:  Diego Santos-García; Mila Oreiro; Patricia Pérez; Gemma Fanjul; Jose Manuel Paz González; María José Feal Painceiras; Carlos Cores Bartolomé; Lorena Valdés Aymerich; Carlos García Sancho; Maria Del Mar Castellanos Rodrigo
Journal:  Mov Disord       Date:  2020-09-22       Impact factor: 9.698

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.